PDCD4 interacting with PIK3CB and CTSZ promotes the apoptosis of multiple myeloma cells

Author:

Liu Liyuan12ORCID,Feng Xiumei3ORCID,Fan Chenliu12ORCID,Kong Dexiao12ORCID,Feng Xiaoli4ORCID,Sun Chenxi12ORCID,Xu Yaqi12ORCID,Li Binggen5ORCID,Jiang Yang12ORCID,Zheng Chengyun12ORCID

Affiliation:

1. Department of Hematology The Second Hospital of Shandong University Jinan Shandong China

2. Institute of Biotherapy for Hematological Malignancy Shandong University Jinan Shandong China

3. Department of Hematology The Fourth People's Hospital of Jinan City Jinan Shandong China

4. Department of Clinical Laboratory The Second Hospital of Shandong University Jinan Shandong China

5. R&D Department Weihai Zhengsheng Biotechnology Co., Ltd Weihai China

Abstract

AbstractThe role of programmed cell death 4 (PDCD4) in multiple myeloma (MM) development remains unknown. Here, we investigated its role and action mechanism in MM. Bioinformatic analysis indicated that patients with MM and high PDCD4 expression had higher overall survival than those with low PDCD4 expression. PDCD4 expression promoted MM cell apoptosis and inhibited their viability in vitro and tumor growth in vivo. RNA‐binding protein immunoprecipitation sequencing analysis showed that PDCD4 is bound to the 5′ UTR of the apoptosis‐related genes PIK3CB, Cathepsin Z (CTSZ), and X‐chromosome‐linked apoptosis inhibitor (XIAP). PDCD4 knockdown reduced the cell apoptosis rate, which was rescued by adding PIK3CB, CTSZ, or XIAP inhibitors. Dual luciferase reporter assays confirmed the internal ribosome entry site (IRES) activity of the 5′ UTRs of PIK3CB and CTSZ. An RNA pull‐down assay confirmed binding of the 5′ UTR of PIK3CB and CTSZ to PDCD4, identifying the specific binding fragments. PDCD4 is expected to promote MM cell apoptosis by binding to the IRES domain in the 5′ UTR of PIK3CB and CTSZ and inhibiting their translation. Our findings suggest that PDCD4 plays an important role in MM development by regulating the expression of PIK3CB, CTSZ, and XIAP, and highlight new potential molecular targets for MM treatment.

Funder

Key Technology Research and Development Program of Shandong Province

National Natural Science Foundation of China

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3